Barclays Rates Hinge Health (HNGE) buy, $70 Price Target

Barclays has reaffirmed its buy rating for Hinge Health, setting a target price of $70 as shares trade at $68.35, a 2.41% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:13 PM EDT · Updated Jun 16, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays rated Hinge Health, Inc. ($HNGE) "buy" with a $70 price target on June 11, 2026.

Since the rating, $HNGE is up 7.2% after 1 week, up 39.0% after 1 month and up 53.1% to date (from the $64.75 close on Jun 11, 2026).

HNGE Hinge Health, Inc.

$99.16 +117.65% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Barclays reiterated its buy rating on Hinge Health, Inc. (NYSE: HNGE), maintaining a price target of $70, while shares are currently at $68.35.
Barclays's $70 price target implies 2.41% upside from Hinge Health, Inc.'s ($HNGE) current $68.35 share price.
Hinge Health's shares are well above their 52-week low of $30.08 but below the high of $107, indicating volatility in the stock's performance.
Analysts have a consensus buy recommendation for Hinge Health, with a mean target price of $112.13, showing overall confidence in the company's growth.

Get $HNGE trade alerts by text

We text you when insiders, Congress or big funds trade $HNGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures

Barclays Reiterates Buy Rating

On June 11, 2026, Barclays reiterated its buy rating for Hinge Health, Inc. (NYSE: HNGE), setting a target price of $70. The shares are currently trading at $68.35. This continued confidence from Barclays aligns with a generally positive outlook from Wall Street on the stock.

How Hinge Health Stands Out

The reiteration of the buy rating comes as Hinge Health currently operates in the health information services industry. The company focuses on automating care delivery and addressing musculoskeletal issues through its technology platform. This unique approach makes it a key player in the growing healthcare technology sector. With a market cap of approximately $8.47 billion and a P/E ratio around 34.64, Hinge Health shows strong financial metrics despite recent trading fluctuations.

Analysts Set New Price Targets

Barclays is not alone in its support for Hinge Health. Other firms have also maintained positive ratings. On October 16, 2026, Keybanc maintained its overweight rating with a target raised to $140. Barclays itself raised its target to $110 on October 12, 2026, from a previous $100. Additionally, Needham maintained a buy rating with a target of $115, up from $97, on September 30, 2026. This collective analyst support reflects strong conviction in Hinge Health's potential for growth in the coming quarters.

Stock Performance Context

Currently, Hinge Health's stock price of $68.35 is positioned significantly above its 52-week low of $30.08 but well below its 52-week high of $107. The stock trades below its 50-day moving average of $92.61, suggesting it may be undervalued in the eyes of some analysts following recent volatility.

12-month forecast

$HNGE price target

Hinge Health, Inc. daily closes and this analyst's $70 target. Not advice.

Upcoming Earnings

Hinge Health is scheduled to report its next earnings on November 2, 2026. Investors will be watching closely for any insights into the company's financial health and growth strategies following this upcoming report.

What Hinge Health, Inc. Does

Hinge Health, headquartered in San Francisco, CA, specializes in delivering automated musculoskeletal care using advanced technology. The company has grown significantly since its founding in 2012, employing over 1,400 people focused on improving patient outcomes through innovative solutions.

What to Watch at Hinge Health, Inc.

As Hinge Health approaches its next earnings date, market watchers should keep an eye on any updates from analysts regarding target prices and ratings. The repeated support from Barclays and other firms indicates strong interest in the company's future performance and strategy.